[go: up one dir, main page]

EP4114379A4 - Procédés et compositions pour traiter un trouble de l'usage du cannabis et atténuer les symptomes du sevrage des cannabinoïdes - Google Patents

Procédés et compositions pour traiter un trouble de l'usage du cannabis et atténuer les symptomes du sevrage des cannabinoïdes Download PDF

Info

Publication number
EP4114379A4
EP4114379A4 EP21765401.1A EP21765401A EP4114379A4 EP 4114379 A4 EP4114379 A4 EP 4114379A4 EP 21765401 A EP21765401 A EP 21765401A EP 4114379 A4 EP4114379 A4 EP 4114379A4
Authority
EP
European Patent Office
Prior art keywords
attenuate
compositions
methods
use disorders
cannabis use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21765401.1A
Other languages
German (de)
English (en)
Other versions
EP4114379A1 (fr
Inventor
Ginger D. CONSTANTINE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PleoPharma Inc
Original Assignee
PleoPharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PleoPharma Inc filed Critical PleoPharma Inc
Priority claimed from PCT/US2021/020921 external-priority patent/WO2021178700A1/fr
Publication of EP4114379A1 publication Critical patent/EP4114379A1/fr
Publication of EP4114379A4 publication Critical patent/EP4114379A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
EP21765401.1A 2020-03-04 2021-03-04 Procédés et compositions pour traiter un trouble de l'usage du cannabis et atténuer les symptomes du sevrage des cannabinoïdes Pending EP4114379A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062985097P 2020-03-04 2020-03-04
PCT/US2021/020921 WO2021178700A1 (fr) 2020-03-04 2021-03-04 Procédés et compositions pour traiter un trouble de l'usage du cannabis et atténuer les symptomes du sevrage des cannabinoïdes

Publications (2)

Publication Number Publication Date
EP4114379A1 EP4114379A1 (fr) 2023-01-11
EP4114379A4 true EP4114379A4 (fr) 2024-01-17

Family

ID=77555295

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21765401.1A Pending EP4114379A4 (fr) 2020-03-04 2021-03-04 Procédés et compositions pour traiter un trouble de l'usage du cannabis et atténuer les symptomes du sevrage des cannabinoïdes

Country Status (8)

Country Link
US (2) US11197846B2 (fr)
EP (1) EP4114379A4 (fr)
KR (1) KR20220163384A (fr)
CN (1) CN115605195A (fr)
AU (1) AU2021230540A1 (fr)
CA (1) CA3170635A1 (fr)
IL (1) IL296166A (fr)
MX (1) MX2022010960A (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12268659B2 (en) * 2020-03-04 2025-04-08 Pleopharma, Inc. Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal
AU2021230540A1 (en) 2020-03-04 2022-10-13 Pleopharma, L.L.C. Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal
WO2023235833A1 (fr) * 2022-06-03 2023-12-07 Pctrx, Inc. Compositions polycannabinoïdes et leurs utilisations

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668224A (en) 1970-07-02 1972-06-06 Theodor Petrzilka PROCESS OF PRODUCING 6a, 10a-TRANS-6a,7,8,10a-TETRAHYDRODIBENZO (b,d)-PYRANS
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
DE3305755A1 (de) 1983-02-19 1984-08-23 Gödecke AG, 1000 Berlin N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems
US4931283A (en) 1983-12-22 1990-06-05 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US5230897A (en) 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5360648A (en) 1993-06-24 1994-11-01 The Dow Chemical Company Pouch for packaging flowable materials
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6008383A (en) 1998-10-26 1999-12-28 University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol esters
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
JP2005526715A (ja) 2002-02-01 2005-09-08 レゾリューション ケミカルズ リミテッド Δ９−テトラヒドロカンナビノールの製造
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
AU2008317336A1 (en) 2007-10-26 2009-04-30 The Scripps Research Institute Methods for treating substance dependence
CA2751627A1 (fr) * 2009-02-06 2010-08-12 Egalet Ltd. Compositions pharmaceutiques resistant a une maltraitance
WO2012116277A1 (fr) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Modulateurs du récepteur cannabinoïde
EP2934512B1 (fr) 2012-12-18 2021-11-24 Kotzker Consulting LLC Utilisation de cannabinoïdes et de terpènes pour le traitement d'une toxicité d'organophosphate et de carbamate
US20180147141A1 (en) 2016-11-29 2018-05-31 Axim Biotechnologies, Inc. Chewing gum composition comprising cannabinoids and gabapentin
WO2021178700A1 (fr) 2020-03-04 2021-09-10 Pleopharma, L.L.C. Procédés et compositions pour traiter un trouble de l'usage du cannabis et atténuer les symptomes du sevrage des cannabinoïdes
AU2021230540A1 (en) 2020-03-04 2022-10-13 Pleopharma, L.L.C. Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BONNET UDO ET AL: "The cannabis withdrawal syndrome: current insights", SUBSTANCE ABUSE AND REHABILITATION, vol. Volume 8, 1 April 2017 (2017-04-01), pages 9 - 37, XP093309401, ISSN: 1179-8467, Retrieved from the Internet <URL:https://www.dovepress.com/getfile.php?fileID=36222> [retrieved on 20250901], DOI: 10.2147/SAR.S109576 *
HANEY MARGARET ET AL: "Nabilone Decreases Marijuana Withdrawal and a Laboratory Measure of Marijuana Relapse", vol. 38, no. 8, 27 March 2013 (2013-03-27), Cham, pages 1557 - 1565, XP093107980, ISSN: 0893-133X, Retrieved from the Internet <URL:https://www.nature.com/articles/npp201354.pdf> [retrieved on 20231201], DOI: 10.1038/npp.2013.54 *
KRAFT B ET AL: "Der Einfluss von Cannabis und Cannabinoiden auf An�sthesie und Analgesie in der perioperativen Phase", SCHMERZ, DER, SPRINGER VERLAG, BERLIN, DE, vol. 34, no. 4, 3 March 2020 (2020-03-03), pages 314 - 318, XP037207558, ISSN: 0932-433X, [retrieved on 20200303], DOI: 10.1007/S00482-020-00449-X *
L�VESQUE ANNIE ET AL: "When and How to Treat Possible Cannabis Use Disorder", vol. 102, no. 4, 1 July 2018 (2018-07-01), US, pages 667 - 681, XP093107974, ISSN: 0025-7125, Retrieved from the Internet <URL:https://dx.doi.org/10.1016/j.mcna.2018.02.009> [retrieved on 20231201], DOI: 10.1016/j.mcna.2018.02.009 *
MASON BARBARA J ET AL: "A Proof-of-Concept Randomized Controlled Study of Gabapentin: Effects on Cannabis Use, Withdrawal and Executive Function Deficits in Cannabis-Dependent Adults", NEUROPSYCHOPHARMACOLOGY, vol. 37, no. 7, 29 February 2012 (2012-02-29), Cham, pages 1689 - 1698, XP093309403, ISSN: 0893-133X, Retrieved from the Internet <URL:https://www.nature.com/articles/npp201214.pdf> [retrieved on 20250901], DOI: 10.1038/npp.2012.14 *
See also references of WO2021178700A1 *

Also Published As

Publication number Publication date
US20220273612A1 (en) 2022-09-01
IL296166A (en) 2022-11-01
CN115605195A (zh) 2023-01-13
CA3170635A1 (fr) 2021-09-10
KR20220163384A (ko) 2022-12-09
EP4114379A1 (fr) 2023-01-11
MX2022010960A (es) 2022-11-16
US20210275492A1 (en) 2021-09-09
AU2021230540A1 (en) 2022-10-13
US11931334B2 (en) 2024-03-19
US11197846B2 (en) 2021-12-14

Similar Documents

Publication Publication Date Title
EP4114379A4 (fr) Procédés et compositions pour traiter un trouble de l&#39;usage du cannabis et atténuer les symptomes du sevrage des cannabinoïdes
EP4203990A4 (fr) Méthodes et compositions pour le traitement du glioblastome
EP4415755A4 (fr) Compositions ciblant ace2 et méthodes de traitement de la covid-19
EP3934615A4 (fr) Compositions et méthodes de traitement de l&#39;acné
EP3923907C0 (fr) Compositions et procédés pour le traitement de la néovascularisation oculaire
EP4408412A4 (fr) Compositions et procédés de traitement de céphalées
EP4171606A4 (fr) Compositions et méthodes de traitement de la covid-19
EP3986439A4 (fr) Compositions et méthodes utiles dans le traitement de maladies du cerveau
EP4340860A4 (fr) Compositions et méthodes de traitement de la neuropathie
EP3979996A4 (fr) Méthodes et compositions de traitement de troubles de la vue
EP3972573A4 (fr) Compositions et procédés utilisant des cannabinoïdes pour traiter le bégaiement et les symptômes du syndrome de la tourette
EP4304612A4 (fr) Compositions et procédés d&#39;évaluation et de traitement d&#39;un dysfonctionnement des lymphocytes t
EP4188346A4 (fr) Compositions de nobiletine et méthodes pour le traitement et la prévention de la covid-19 et de pathologies associées
EP4518846A4 (fr) Compositions et méthodes de traitement de l&#39;épilepsie
EP4429763A4 (fr) Compositions et méthodes pour traiter un saignement et des troubles de saignement
EP4114411A4 (fr) Compositions et méthodes pour le traitement du cancer du pancréas
EP3568020A4 (fr) Compositions et méthodes pour le traitement d&#39;états démyélinisants
EP4157238A4 (fr) Compositions ophtalmologiques topiques et procédés de traitement d&#39;angiogenèse anormale
EP4308116A4 (fr) Méthodes et compositions de traitement de maladies oculaires
EP4340835A4 (fr) Méthodes et compositions pour le traitement d&#39;une maladie cardiovasculaire
EP4099997A4 (fr) Méthodes et compositions pour le traitement de maladies
EP4153207A4 (fr) Procédés et compositions pour traiter la fuite vasculaire
EP4100029A4 (fr) Compositions et procédés pour les utiliser pour le traitement de la mammite
EP4262786A4 (fr) Compositions de psil3301-4-2 et méthodes de traitement de troubles de l&#39;anxiété
EP4326757A4 (fr) Nouvelles compositions et nouvelles méthodes de traitement d&#39;infections à coronavirus

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221004

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085129

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20231220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/30 20060101ALI20231214BHEP

Ipc: A61K 31/352 20060101ALI20231214BHEP

Ipc: A61K 31/195 20060101AFI20231214BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250910